Thompson Siegel & Walmsley LLC Has $5.28 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Thompson Siegel & Walmsley LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,292 shares of the medical research company’s stock after acquiring an additional 4,000 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in IQVIA were worth $5,283,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PGGM Investments increased its holdings in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares during the period. Simplify Asset Management Inc. lifted its holdings in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Quadrature Capital Ltd bought a new position in IQVIA in the first quarter valued at approximately $3,365,000. Raymond James & Associates raised its position in IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares in the last quarter. Finally, Versor Investments LP acquired a new stake in shares of IQVIA in the 3rd quarter valued at $1,328,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $197.57 on Friday. The firm has a market cap of $35.86 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 1.97 and a beta of 1.51. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The business’s 50 day moving average price is $223.40 and its two-hundred day moving average price is $227.35.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on IQV shares. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird dropped their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. BTIG Research lowered their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.